A Surge in GLP-1 Demand
GLP-1 medications (initially developed for type 2 diabetes) have rapidly gained popularity in the UK and Ireland for both diabetes and weight management. Their high efficacy and rising clinical endorsements have driven significant year-on-year uptake.
▶ In the UK, private prescriptions for GLP-1 drugs have surged, with Mounjaro® dominating around 70% of private obesity drug sales, used weekly by approximately half a million Britons.
▶ In Ireland, pharmaceutical output is scaling up. Eli Lilly invested US$1.8 billion across Kinsale and Limerick facilities to boost production of obesity and diabetes treatments such as Mounjaro® and Zepbound®, and Novo Nordisk acquired a manufacturing plant in Athlone from Alkermes to expand capacity for diabetes treatments, signalling growing local infrastructure.
▶ At the European level, GLP‑1 drugs are now widely available across key markets, including France, Spain, Italy, Germany, and the UK, with consumer and prescribing patterns shifting rapidly.
This sharp increase in demand has also created challenges. The European Medicines Agency (EMA) recently acknowledged persistent shortages across the EU, leading to coordinated efforts to redistribute supplies and secure continued patient access.
These trends reflect a broader global market trajectory and reinforce the need for resilient, scalable cold-chain infrastructure to support continued access and distribution.
The Critical Need for Cold‑Chain Integrity
GLP-1 medications are highly temperature-sensitive. To maintain efficacy and patient safety, they must be stored within:
+2 °C to +8 °C — typical refrigeration range
+15 °C to +25 °C — in some cases, controlled room temperature
Even slight deviations can degrade the drug, affecting its potency and compliance. To avert risks, best-practice logistics emphasise:
▶ Precise temperature control
▶ Insulated, gel-packed packaging
▶ Minimised internal voids for thermal consistency
▶ Real-time monitoring with alerts
▶ Full validation and documentation compliant with FDA, EMA and GDP standards
These mandates drive the design of cold-chain solutions throughout the GLP-1 supply chain.
CRS Pharma’s Differentiation in a High-Demand Market
CRS Pharma offers modular, pre-validated cold store solutions tailored to GLP‑1 medication logistics, meeting both demand surges and regulatory expectations.
▶ Rapid deployment across the UK and Ireland is ideal for sudden demand spikes.
▶ Consistent temperature performance: Each unit undergoes temperature mapping as part of the pre-validation process, ensuring consistent temperature distribution within the specified range.
▶ Scalable and modular solutions, providing storage when and where it is needed without capital-heavy infrastructure.
▶ Compliance support with audit-ready documentation, meeting global regulatory standards.
We offer the assurance manufacturers and distributors need to handle sensitive biologics confidently.
Why Modular Climate-Controlled Solutions Are Ideal for GLP‑1 Logistics
As demand for GLP‑1 medications continues to rise, climate-controlled modular storage provides a strategic advantage – both operationally and commercially.
Perfect Storage Environment
Our in-house engineering team delivers tailored, fully adaptable solutions to meet individual client requirements. All units are pre-validated, and we have successfully supported leading global pharmaceutical companies, ensuring alignment with their strict regulatory and compliance standards. We offer full technical and service support, and our clients can rely on us for consistent performance and operational peace of mind.
Logistics Resilience and Cost Efficiency
In addition to improving supply chain agility, decentralised storage enables pharmaceutical distributors to build stock in advance of price increases or market fluctuations.
With GLP-1 prices on the rise, this flexibility is more critical than ever. For example, Eli Lilly is increasing the UK price of Mounjaro by 170% due to soaring demand, putting added pressure on the sector to secure stock early.
Strategic Inventory Buffering
Modular storage enables distributors and suppliers to establish buffer stock closer to end destinations, reducing fulfilment delays and supporting continuity during demand surges or manufacturing interruptions.
With validated performance, regulatory alignment, and rapid deployability, CRS Pharma’s modular solutions are an essential asset for any organisation handling GLP-1 medications in a fast-moving market.
We would love to hear about your cold storage needs! Get in touch and learn how our knowledgeable team can help you boost your growth and success.
Published by: CRS Pharma Solutions